Article

Daily Medication Pearl: Vraylar (Cariprazine)

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Medication Pearl of the Day: Vraylar (Cariprazine)

Indication: Vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults, for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Insight:

  • Dosing: Patients can take Vraylar at 1.5 mg to 6 mg daily.
  • Dosage forms: Capsules of Vraylar come in dosages of 1.5 mg, 3 mg, 4.5 mg, and 6 mg.
  • Adverse events (AEs): Most common AEs include extrapyramidal symptoms and akathisia, extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness.
  • Mechanism of action: The efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
  • Manufacturer: Forest Laboratories

Source:

vraylar_pi.pdf (allergan.com)

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com